Calamos Advisors
TPTX

Calamos Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Calamos Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-19,366
Closed -$2.36M – 985
2020
Q4 		$2.36M Buy
+19,366
New +$2.12M 0.01% 621

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Calamos Advisors's TPTX Position: Q1 2021 in Review

Calamos Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2021, closing a stake of 19,366 shares — an estimated $2.36M sold.

Calamos Advisors first reported a position in TPTX in Q4 2020 and held it in 1 quarter. The position peaked at $2.36M in Q4 2020. 202 funds tracked by Wall St. Rank hold TPTX as of Q1 2021.

  • Calamos Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Calamos Advisors sold 19,366 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2.36M.
  • Calamos Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Calamos Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $2.36M in Q4 2020.
  • 202 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Calamos Advisors's 13F filing for Q1 2021, filed 12 Apr 2021.